InMed Pharmaceuticals (
CSE: IN,
Stock Forum) made a significant move to bolster its strategic brain power when the clinical stage biopharmaceutical company announced today that it had appointed Pater Mountford to oversee the company’s European Market plans.
According to the
news release, Mountford, the former GW Pharmaceuticals financier, investor and Non-Executive Director, will leverage his successful track record in cannabinoid biotech and provide capital markets counsel and advisory for the company.
Mountford, already instrumental with finding the necessary funding for GW Pharmaceuticals’ business development and IPO offering, will also assist in upping shareholder value of InMed through advising the company on European financing opportunities.
Currently, Mountford is a Non-Executive Director of RWS Holdings, one of the top patent translation and search companies and a top 50 company on AIM. He was also an integral force in RWS’ IPO in 2003 and is the founder of leading European e-learning company, Learning Technologies Group. He has deep knowledge and experience in all areas of corporate finance including fund-raising, acquisitions, disposals, MBOs, MBIs and flotations.
Peter Mountford on his reasoning behind accepting the appointment, “I am attracted to InMed's growing therapeutic pipeline and accelerated development strategy, as well as the impressive team of executives and advisors that the company has assembled. Their cutting-edge approach of therapy identification and development based on their proprietary platform technology is particularly compelling.”
He then added, “As the market for cannabinoid-based therapeutics continues to expand globally, I look forward to supporting InMed with the expectation that my significant experience investing directly and securing investments in this sector will result in enhanced visibility for the company among European investors.”
Company President and CEO, Craig Schnieder, illustrated the corporate benefits this new appointment brought, “Aligning InMed with Peter Mountford brings another highly influential leader in cannabinoid based therapy development to our company. Specifically, we look forward to benefitting from Peter's proven financing capabilities and deep knowledge of European investors as we seek to expand InMed's shareholder base and attract new capital.”
InMed Pharmaceuticals was in
the news recently when the Vancouver-based company announced qualifying for electronic trading in the U.S. five days ago.
Currently there are 52.9m outstanding shares with a market cap of $15.9 million.
FULL DISCLOSURE: InMed Pharmaceuticals is a Stockhouse Publishing client.